We found IDH1 mutants presented 3.6-fold more, 60.5% in MGMT methylated glioma cases as compared with 27.3% in unmethylated cases and in this context, Martin et al. [44] found a similar scenario of correlation with the same frequency of IDH1 mutations (62%) in MGMT promoter-methylated tumors compared with 10% in unmethylated ones. This evidence concerns the gene MGMT and central nervous system cancer.